Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Preconditioning in the Rhesus Macaque Induces a Proteomic Signature Following Cerebral Ischemia that Is Associated with Neuroprotection.

Stevens SL, Liu T, Bahjat FR, Petyuk VA, Schepmoes AA, Sontag RL, Gritsenko MA, Wu C, Wang S, Shukla AK, Jacobs JM, Smith RD, Rodland KD, Alexander West G, Kohama SG, Glynn C, Stenzel-Poore MP.

Transl Stroke Res. 2019 Aug;10(4):440-448. doi: 10.1007/s12975-018-0670-7. Epub 2018 Oct 19.

PMID:
30341719
2.

Translational Stroke Research: Vision and Opportunities.

Bosetti F, Koenig JI, Ayata C, Back SA, Becker K, Broderick JP, Carmichael ST, Cho S, Cipolla MJ, Corbett D, Corriveau RA, Cramer SC, Ferguson AR, Finklestein SP, Ford BD, Furie KL, Hemmen TM, Iadecola C, Jakeman LB, Janis S, Jauch EC, Johnston KC, Kochanek PM, Kohn H, Lo EH, Lyden PD, Mallard C, McCullough LD, McGavern LM, Meschia JF, Moy CS, Perez-Pinzon MA, Ramadan I, Savitz SI, Schwamm LH, Steinberg GK, Stenzel-Poore MP, Tymianski M, Warach S, Wechsler LR, Zhang JH, Koroshetz W.

Stroke. 2017 Sep;48(9):2632-2637. doi: 10.1161/STROKEAHA.117.017112. Epub 2017 Jul 27. Review. No abstract available.

3.

TLR sensing of bacterial spore-associated RNA triggers host immune responses with detrimental effects.

Choo MK, Sano Y, Kim C, Yasuda K, Li XD, Lin X, Stenzel-Poore M, Alexopoulou L, Ghosh S, Latz E, Rifkin IR, Chen ZJ, Stewart GC, Chong H, Park JM.

J Exp Med. 2017 May 1;214(5):1297-1311. doi: 10.1084/jem.20161141. Epub 2017 Apr 11.

4.

Preclinical Development of a Prophylactic Neuroprotective Therapy for the Preventive Treatment of Anticipated Ischemia-Reperfusion Injury.

Bahjat FR, Alexander West G, Kohama SG, Glynn C, Urbanski HF, Hobbs TR, Earl E, Stevens SL, Stenzel-Poore MP.

Transl Stroke Res. 2017 Aug;8(4):322-333. doi: 10.1007/s12975-017-0532-8. Epub 2017 Apr 5.

5.

Cytosolic Receptor Melanoma Differentiation-Associated Protein 5 Mediates Preconditioning-Induced Neuroprotection Against Cerebral Ischemic Injury.

Gesuete R, Christensen SN, Bahjat FR, Packard AE, Stevens SL, Liu M, Salazar AM, Stenzel-Poore MP.

Stroke. 2016 Jan;47(1):262-6. doi: 10.1161/STROKEAHA.115.010329. Epub 2015 Nov 12.

6.

GDF10 is a signal for axonal sprouting and functional recovery after stroke.

Li S, Nie EH, Yin Y, Benowitz LI, Tung S, Vinters HV, Bahjat FR, Stenzel-Poore MP, Kawaguchi R, Coppola G, Carmichael ST.

Nat Neurosci. 2015 Dec;18(12):1737-45. doi: 10.1038/nn.4146. Epub 2015 Oct 26.

7.

Role of Circulating Immune Cells in Stroke and Preconditioning-Induced Protection.

Gesuete R, Stevens SL, Stenzel-Poore MP.

Acta Neurochir Suppl. 2016;121:39-44. doi: 10.1007/978-3-319-18497-5_7. Review.

8.

CpG preconditioning regulates miRNA expression that modulates genomic reprogramming associated with neuroprotection against ischemic injury.

Vartanian KB, Mitchell HD, Stevens SL, Conrad VK, McDermott JE, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2015 Feb;35(2):257-66. doi: 10.1038/jcbfm.2014.193. Epub 2014 Nov 12.

9.

Reprogramming the response to stroke by preconditioning.

Stevens SL, Vartanian KB, Stenzel-Poore MP.

Stroke. 2014 Aug;45(8):2527-31. doi: 10.1161/STROKEAHA.114.002879. Epub 2014 Jun 17. Review. No abstract available.

10.

Matrix effects in biological mass spectrometry imaging: identification and compensation.

Lanekoff I, Stevens SL, Stenzel-Poore MP, Laskin J.

Analyst. 2014 Jul 21;139(14):3528-32. doi: 10.1039/c4an00504j.

11.

Toll-like receptors and ischemic brain injury.

Gesuete R, Kohama SG, Stenzel-Poore MP.

J Neuropathol Exp Neurol. 2014 May;73(5):378-86. doi: 10.1097/NEN.0000000000000068. Review.

12.

Changes in spontaneous activity assessed by accelerometry correlate with extent of cerebral ischemia-reperfusion injury in the nonhuman primate.

Urbanski HF, Kohama SG, West GA, Glynn C, Williams-Karnesky RL, Earl E, Neuringer MN, Renner L, Weiss A, Stenzel-Poore M, Bahjat FR.

Transl Stroke Res. 2012 Dec;3(4):442-51. doi: 10.1007/s12975-012-0191-8.

13.

Steps to translate preconditioning from basic research to the clinic.

Bahjat FR, Gesuete R, Stenzel-Poore MP.

Transl Stroke Res. 2013 Feb;4(1):89-103. doi: 10.1007/s12975-012-0223-4. Epub 2012 Nov 2. Review.

14.

Poly-ICLC preconditioning protects the blood-brain barrier against ischemic injury in vitro through type I interferon signaling.

Gesuete R, Packard AE, Vartanian KB, Conrad VK, Stevens SL, Bahjat FR, Yang T, Stenzel-Poore MP.

J Neurochem. 2012 Nov;123 Suppl 2:75-85. doi: 10.1111/j.1471-4159.2012.07946.x.

15.

Modeling dynamic regulatory processes in stroke.

McDermott JE, Jarman K, Taylor R, Lancaster M, Shankaran H, Vartanian KB, Stevens SL, Stenzel-Poore MP, Sanfilippo A.

PLoS Comput Biol. 2012;8(10):e1002722. doi: 10.1371/journal.pcbi.1002722. Epub 2012 Oct 11.

16.

TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning.

Packard AE, Leung PY, Vartanian KB, Stevens SL, Bahjat FR, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2012 Dec;32(12):2193-200. doi: 10.1038/jcbfm.2012.140. Epub 2012 Sep 26.

17.

Identification and validation of Ifit1 as an important innate immune bottleneck.

McDermott JE, Vartanian KB, Mitchell H, Stevens SL, Sanfilippo A, Stenzel-Poore MP.

PLoS One. 2012;7(6):e36465. doi: 10.1371/journal.pone.0036465. Epub 2012 Jun 20.

18.

Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism.

Leung PY, Stevens SL, Packard AE, Lessov NS, Yang T, Conrad VK, van den Dungen NN, Simon RP, Stenzel-Poore MP.

Stroke. 2012 May;43(5):1383-9. doi: 10.1161/STROKEAHA.111.641522. Epub 2012 Mar 8.

19.

Poly-IC preconditioning protects against cerebral and renal ischemia-reperfusion injury.

Packard AE, Hedges JC, Bahjat FR, Stevens SL, Conlin MJ, Salazar AM, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2012 Feb;32(2):242-7. doi: 10.1038/jcbfm.2011.160. Epub 2011 Nov 16.

20.

LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury.

Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, Stenzel-Poore MP.

J Neuroinflammation. 2011 Oct 14;8:140. doi: 10.1186/1742-2094-8-140.

21.

Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice.

Kaur S, Li J, Stenzel-Poore MP, Ryabinin AE.

Alcohol Clin Exp Res. 2012 Feb;36(2):369-76. doi: 10.1111/j.1530-0277.2011.01610.x. Epub 2011 Sep 6.

22.

Dissociation of corticotropin-releasing factor receptor subtype involvement in sensitivity to locomotor effects of methamphetamine and cocaine.

Giardino WJ, Mark GP, Stenzel-Poore MP, Ryabinin AE.

Psychopharmacology (Berl). 2012 Feb;219(4):1055-63. doi: 10.1007/s00213-011-2433-y. Epub 2011 Aug 11.

23.

Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury.

Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP.

J Neurosci. 2011 Jun 8;31(23):8456-63. doi: 10.1523/JNEUROSCI.0821-11.2011.

24.

Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout mice.

Pastor R, Reed C, Burkhart-Kasch S, Li N, Sharpe AL, Coste SC, Stenzel-Poore MP, Phillips TJ.

Psychopharmacology (Berl). 2011 Nov;218(1):169-77. doi: 10.1007/s00213-011-2284-6. Epub 2011 Apr 13.

25.

Corticotropin-releasing hormone (CRH) transgenic mice display hyperphagia with increased Agouti-related protein mRNA in the hypothalamic arcuate nucleus.

Nakayama S, Nishiyama M, Iwasaki Y, Shinahara M, Okada Y, Tsuda M, Okazaki M, Tsugita M, Taguchi T, Makino S, Stenzel-Poore MP, Hashimoto K, Terada Y.

Endocr J. 2011;58(4):279-86. Epub 2011 Mar 5.

26.

CRF receptor antagonist astressin-B reverses and prevents alopecia in CRF over-expressing mice.

Wang L, Million M, Rivier J, Rivier C, Craft N, Stenzel-Poore MP, Taché Y.

PLoS One. 2011 Feb 16;6(2):e16377. doi: 10.1371/journal.pone.0016377.

27.

Toll-like receptor tolerance as a mechanism for neuroprotection.

Vartanian K, Stenzel-Poore M.

Transl Stroke Res. 2010 Dec 1;1(4):252-260.

28.

Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke.

Bahjat FR, Williams-Karnesky RL, Kohama SG, West GA, Doyle KP, Spector MD, Hobbs TR, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2011 May;31(5):1229-42. doi: 10.1038/jcbfm.2011.6. Epub 2011 Feb 2.

29.

Defining the players in higher-order networks: predictive modeling for reverse engineering functional influence networks.

McDermott JE, Archuleta M, Stevens SL, Stenzel-Poore MP, Sanfilippo A.

Pac Symp Biocomput. 2011:314-25.

30.

Dissection of corticotropin-releasing factor system involvement in locomotor sensitivity to methamphetamine.

Giardino WJ, Pastor R, Anacker AM, Spangler E, Cote DM, Li J, Stenzel-Poore MP, Phillips TJ, Ryabinin AE.

Genes Brain Behav. 2011 Feb;10(1):78-89. doi: 10.1111/j.1601-183X.2010.00641.x. Epub 2010 Sep 30.

31.

Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Williams-Karnesky RL, Stenzel-Poore MP.

Curr Neuropharmacol. 2009 Sep;7(3):217-27. doi: 10.2174/157015909789152209.

32.

Isolation rearing-induced deficits in contextual fear learning do not require CRF(2) receptors.

Gresack JE, Risbrough VB, Scott CN, Coste S, Stenzel-Poore M, Geyer MA, Powell SB.

Behav Brain Res. 2010 May 1;209(1):80-4. doi: 10.1016/j.bbr.2010.01.018. Epub 2010 Jan 25.

33.
34.

Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3.

Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP.

J Neurosci. 2009 Aug 5;29(31):9839-49. doi: 10.1523/JNEUROSCI.2496-09.2009.

35.

Plasma adiponectin levels are increased despite insulin resistance in corticotropin-releasing hormone transgenic mice, an animal model of Cushing syndrome.

Shinahara M, Nishiyama M, Iwasaki Y, Nakayama S, Noguchi T, Kambayashi M, Okada Y, Tsuda M, Stenzel-Poore MP, Hashimoto K, Terada Y.

Endocr J. 2009;56(7):879-86. Epub 2009 Jun 24.

36.

A new model of cortical stroke in the rhesus macaque.

West GA, Golshani KJ, Doyle KP, Lessov NS, Hobbs TR, Kohama SG, Pike MM, Kroenke CD, Grafe MR, Spector MD, Tobar ET, Simon RP, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2009 Jun;29(6):1175-86. doi: 10.1038/jcbfm.2009.43. Epub 2009 Apr 22.

37.

CRF enhancement of GIRK channel-mediated transmission in dopamine neurons.

Beckstead MJ, Gantz SC, Ford CP, Stenzel-Poore MP, Phillips PE, Mark GP, Williams JT.

Neuropsychopharmacology. 2009 Jul;34(8):1926-35. doi: 10.1038/npp.2009.25. Epub 2009 Mar 11.

38.

Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia.

Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP.

Stroke. 2009 Mar;40(3 Suppl):S34-7. doi: 10.1161/STROKEAHA.108.534917. Epub 2008 Dec 8.

39.

CRF1 and CRF2 receptors are required for potentiated startle to contextual but not discrete cues.

Risbrough VB, Geyer MA, Hauger RL, Coste S, Stenzel-Poore M, Wurst W, Holsboer F.

Neuropsychopharmacology. 2009 May;34(6):1494-503. doi: 10.1038/npp.2008.205. Epub 2008 Nov 19.

40.

Toll-like receptor signaling in endogenous neuroprotection and stroke.

Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP.

Neuroscience. 2009 Feb 6;158(3):1007-20. doi: 10.1016/j.neuroscience.2008.07.067. Epub 2008 Aug 12. Review.

41.

Corticotropin-releasing factor-overexpressing mice exhibit reduced neuronal activation in the arcuate nucleus and food intake in response to fasting.

Stengel A, Goebel M, Million M, Stenzel-Poore MP, Kobelt P, Mönnikes H, Taché Y, Wang L.

Endocrinology. 2009 Jan;150(1):153-60. doi: 10.1210/en.2008-0723. Epub 2008 Sep 11.

42.

Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: a urocortin1-independent mechanism.

Pastor R, McKinnon CS, Scibelli AC, Burkhart-Kasch S, Reed C, Ryabinin AE, Coste SC, Stenzel-Poore MP, Phillips TJ.

Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9070-5. doi: 10.1073/pnas.0710181105.

43.

Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke.

Doyle KP, Yang T, Lessov NS, Ciesielski TM, Stevens SL, Simon RP, King JS, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2008 Jun;28(6):1235-48. doi: 10.1038/jcbfm.2008.17. Epub 2008 Mar 26.

44.

Mechanisms of ischemic brain damage.

Doyle KP, Simon RP, Stenzel-Poore MP.

Neuropharmacology. 2008 Sep;55(3):310-8. doi: 10.1016/j.neuropharm.2008.01.005. Epub 2008 Jan 25. Review.

45.

Toll-like receptor 9: a new target of ischemic preconditioning in the brain.

Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule JL, Lessov NS, Simon RP, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2008 May;28(5):1040-7. doi: 10.1038/sj.jcbfm.9600606. Epub 2008 Jan 9.

46.

Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.

Marsh BJ, Stenzel-Poore MP.

Curr Opin Pharmacol. 2008 Feb;8(1):8-13. Epub 2007 Nov 5. Review.

47.

Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury.

Doyle KP, Suchland KL, Ciesielski TM, Lessov NS, Grandy DK, Scanlan TS, Stenzel-Poore MP.

Stroke. 2007 Sep;38(9):2569-76. Epub 2007 Aug 9.

PMID:
17690312
48.

Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest.

Hickey EJ, You X, Kaimaktchiev V, Stenzel-Poore M, Ungerleider RM.

J Thorac Cardiovasc Surg. 2007 Jun;133(6):1588-96. Epub 2007 May 2.

49.

Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance.

Rosenzweig HL, Minami M, Lessov NS, Coste SC, Stevens SL, Henshall DC, Meller R, Simon RP, Stenzel-Poore MP.

J Cereb Blood Flow Metab. 2007 Oct;27(10):1663-74. Epub 2007 Feb 28.

PMID:
17327883
50.

Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity.

Deussing JM, Kühne C, Pütz B, Panhuysen M, Breu J, Stenzel-Poore MP, Holsboer F, Wurst W.

J Cereb Blood Flow Metab. 2007 Aug;27(8):1476-95. Epub 2007 Feb 7.

PMID:
17293846

Supplemental Content

Loading ...
Support Center